Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours

It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.

Eighteen therapeutics developers launched IPO in 2016, raising $1.2bn in total net proceeds and generating an average return of 10.8% as of June 30. Nine of the companies produced a positive return at mid-year and nine had a negative return versus their IPO stock price. But with only 18 IPOs so far in 2016 versus 34 biopharma first-time offerings at the mid-point of 2015, which raised a total of $2.9bn in net proceeds, investors clearly are responding to the now poor performance of companies that went public last year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

First Quarter M&A Activity Rose On The Strength Of Three Deals

10 Apr 2025

• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

10 Apr 2025

• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

09 Apr 2025

• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

09 Apr 2025

• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

09 Apr 2025

• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.